Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print March 8, 2006, doi:10.1212/01.wnl.0000205596.19540.2c)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000205596.19540.2cv1
66/8/1223    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milone, M.
Right arrow Articles by Engel, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milone, M.
Right arrow Articles by Engel, A. G.
Received October 7, 2005
Accepted January 13, 2006

Novel congenital myasthenic syndromes associated with defects in quantal release

M. Milone MD, PhD, T. Fukuda MD, X.-M. Shen PhD, A. Tsujino MD, J. Brengman BS, and A. G. Engel MD*

From the Department of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, MN.


* To whom correspondence should be addressed. E-mail: age{at}mayo.edu.

Abstract-- Background: Most congenital myasthenic syndromes are caused by defects in postsynaptic or synaptic basal lamina-associated proteins; congenital myasthenic syndromes (CMSs) associated with presynaptic defects are uncommon. Here, the authors describe clinical, electrophysiologic, and morphologic features of two novel and highly disabling CMSs, one determined by presynaptic and the other determined by combined presynaptic and postsynaptic defects. Methods: Microelectrode, single channel patch clamp, immunocytochemical, [125I]{alpha}-bungarotoxin binding, and quantitative electron microscopy studies of endplates were performed. Candidate genes were directly sequenced. Results: Patient 1, a 7-year-old boy, had severe myasthenic symptoms since infancy. Patient 2, a 48-year-old man, had delayed motor milestones and became progressively weaker after age 2 years. Both used wheelchairs and had a 30-50% EMG decrement on 2-Hz stimulation. Evoked quantal release was reduced to approximately 25% of normal in both. In Patient 2, the synaptic response to acetylcholine was further compromised by degeneration of the junctional folds with concomitant loss of the acetylcholine receptor (AChR). A search for mutations in components of the synaptic vesicle release complex and in other candidate proteins failed to identify the molecular basis of the two syndromes. Conclusions: Combined clinical, morphologic, and in vitro electrophysiologic findings define two novel congenital myasthenic syndromes. The molecular basis of these syndromes awaits discovery.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by AAN Enterprises, Inc.